Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 4, 2015, Pages

  Lawrenson, John G ^a   Evans, Jennifer R ^b  

^a CITY UNIVERSITY   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID;

ADVERSE EVENT; AGE RELATED MACULAR DEGENERATION; CLINICAL ASSESSMENT; CLINICAL OUTCOME; DIETARY INTAKE; DISEASE EXACERBATION; FAT INTAKE; FRANCE; HAZARD RATIO; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; UNITED STATES; VISUAL ACUITY; VISUAL IMPAIRMENT; VITAMIN SUPPLEMENTATION; DISEASE COURSE; MACULAR DEGENERATION; META ANALYSIS;

DISEASE PROGRESSION; FATTY ACIDS, OMEGA-3; HUMANS; MACULAR DEGENERATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84944474570     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010015.pub3     Document Type: Review

References (39)

1. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309(19):2005-15.
2. Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBee W, et al. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology 2012;119(11):2282-9.
3. Souied EH, Delcourt C, Querques G, Bassols A, Merle B, Zourdani A, et al. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2 study. Ophthalmology 2013;120(8):1619-31.
4. Arnold C, Winter L, Fröhlich K, Jentsch S, Dawczynski J, Jahreis G, et al. Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmology 2013;131(5):564-72.
5. Feher J, Kovacs B, Kovacs I, Schveoller M, Papale A, Balacco Gabrieli C. Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10. Ophthalmologica 2005;219(3):154-66.
6. García-Layana, A, Recalde S, Alamán AS, Robredo PF. Effects of lutein and docosahexaenoic acid supplementation on macular pigment optical density in a randomized controlled trial. Nutrients 2013;5(2):543-51.
7. Huang LL, Coleman HR, Kim J, de Monasterio F, Wong WT, Schleicher RL, et al. Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. Investigative Ophthalmology and Visual Science 2008;49(9):3864-9.
8. Johnson EJ, Chung HY, Caldarella SM, Snodderly DM. The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation. American Journal of Clinical Nutrition 2008;87(5):1521-9.
9. NCT01258335. Short term ocular safety assessment of high dose omega-3 supplementation for age-related macular degeneration. clinicaltrials.gov/ct2/show/NCT01258335 (accessed 8 June 2012).
10. ISRCTN72331636. The OPAL study: older people and n-3 long-chain polyunsaturated fatty acids. controlled-trials.com/ISRCTN72331636 (accessed 11 June 2012).
11. Scorolli L, Scalinci SZ, Limoli PG, Morara M, Vismara S, Scorolli L, et al. Photodynamic therapy for age related macular degeneration with and without antioxidants [La phototherapie dynamique de la degenerescence maculaire liee a l'age avec ou sans therapie aux antioxydants]. Canadian Journal of Ophthalmology 2002;37(7):399-404.
12. Ziegler R. Supplementary carotinoids and omega-3-fatty acids are ineffective [Zusatzliche carotinoide und omega-3-fettsauren wirkungslos]. Medizinische Monatsschrift fur Pharmazeuten 2013;36(9):348-9.
13. NCT02264938. Drusen morphology changes in nonexudative age-related degeneration using spectral domain optical coherence tomography after oral antioxidants supplementation: one-year results. ClinicalTrials.gov/show/NCT02264938 (accessed 9 February 2015).
14. NCT01169259. Vitamin D and Omega-3 Trial (VITAL). clinicaltrials.gov/ct2/show/NCT01169259 (accessed 9th February 2015).
15. Anonymous. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Controlled Clinical Trials 1999;20(6):573-600.
16. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye 2010;24(11):1692-9.
17. Burdge GC, Jones AE, Wootton SA. Eicosapentaenoic and docosapentaenoic acids are the principal products of alpha-linolenic acid metabolism in young men. British Journal of Nutrition 2002;88(4):355-63.
18. Chong EW, Robman LD, Simpson JA, Hodge AM, Aung KZ, Dolphin TK, et al. Fat consumption and its association with age-related macular degeneration. Archives of Ophthalmology 2009;127(5):674-80.
19. Christen WG, Schaumberg DA, Glynn RJ, Buring JE. Dietary omega-3 fatty acid and fish intake and incident age-related macular degeneration in women. Archives of Ophthalmology 2011;129(7):921-9.
20. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: 10.1002/14651858.CD000253.pub3]
21. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD000254.pub3]
22. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
23. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
24. Hodge WG, Schachter HM, Barnes D, Pan Y, Lowcock EC, Zhang L, et al. Efficacy of omega-3 fatty acids in preventing age-related macular degeneration: a systematic review. Ophthalmology 2006;113(7):1165-72.
25. Hodge WG, Barnes D, Schachter HM, Pan YI, Lowcock EC, Zhang L, et al. Evidence for the effect of omega-3 fatty acids on progression of age-related macular degeneration: a systematic review. Retina 2007;27(2):216-21.
26. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD003177.pub2]
27. Kishan AU, Modjtahedi BS, Martins EN, Modjtahedi SP, Morse LS. Lipids and age-related macular degeneration. Survey of Ophthalmology 2011;56(3):195-213.
28. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin age-related maculopathy grading system. Ophthalmology 1991;98(7):1128-34.
29. Koto T, Nagai N, Mochimaru H, Kurihara T, Izumi-Nagai K, Satofuka S, et al. Eicosapentaenoic acid is anti-inflammatory in preventing choroidal neovascularization in mice. Investigative Ophthalmology and Visual Science 2007;48(9):4328-34.
30. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet 2012;379(9827):1728-38.
31. Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. British Journal of Ophthalmology 2012;96(5):752-6.
32. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
33. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 2012;119(3):571-80.
34. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Progress in Retinal and Eye Research 2005;24(1):87-138.
35. SanGiovanni JP, Agron E, Clemons TE, Chew EY. Omega-3 long-chain polyunsaturated fatty acid intake inversely associated with 12-year progression to advanced age-related macular degeneration. Archives of Ophthalmology 2009; Vol. 127, issue 1:110-2.
36. Tan JS, Wang JJ, Flood V, Mitchell P. Dietary fatty acids and the 10-year incidence of age-related macular degeneration: the Blue Mountains Eye Study. Archives of Ophthalmology 2009;127(5):656-65.
37. Tuo J, Ross RJ, Herzlich AA, Shen D, Ding X, Zhou M, et al. A high omega-3 fatty acid diet reduces retinal lesions in a murine model of macular degeneration. American Journal of Pathology 2009;175(2):799-807.
38. Lawrenson JG, Evans JR. Omega 3 fatty acid supplementation for preventing and slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD010015]
39. Lawrenson JG, Evans JR. Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD010015.pub2]